Q-omics provides the consensus-scored SPRY1 profile across patient tissues and cancer cell-line models. SPRY1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPRY1 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, SPRY1 RNA expression shows 19,747 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, BLCA, and THYM as cancer lineages where SPRY1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPRY1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPRY1 survival associations across molecular data types. SPRY1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPRY1 RNA expression–survival associations across cancer types. High SPRY1 expression shows unfavorable associations in KIRP and LGG, but favorable associations in KIRC, HNSC, SKCM and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SPRY1 RNA expression.
This table summarizes SPRY1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SPRY1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPRY1 shows lower tumor expression in BLCA, KICH and LUSC and higher tumor expression in KIRC, LIHC and THCA. The BLCA box plot shows higher SPRY1 RNA expression in normal versus tumor tissue (log2 FC = −1.948, t-test p < 0.001).
This table shows molecular features associated with SPRY1 in patient tissues and cancer cell lines. In patient samples, SPRY1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPRY1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
